Cue Biopharma downsizes to focus on autoimmune pipeline
Cue Biopharma has instituted strategic restructuring measures with a plan to focus on autoimmune programs and carry out a workforce…
Cue Biopharma has instituted strategic restructuring measures with a plan to focus on autoimmune programs and carry out a workforce…
The University of Nottingham in the UK has announced that a recent clinical trial has demonstrated the effectiveness of a…
Johnson & Johnson (J&J) has released positive results from the Phase III trial of nipocalimab in patients with generalised myasthenia…
US-based biopharmaceutical company Mozart Therapeutics has dosed the first subjects in its Phase Ia/b trial of MTX-101, a CD8 Treg modulator…
Much like the mythological navigator from which it takes its name, Barinthus Biotherapeutics is steering a new course of pipeline…
For 20 years, AbbVie’s Humira (adalimumab) has been one of the world’s top-selling products. However, the US drug expiry in…
Zai Lab has dosed the first subject in a Phase II clinical trial of ZL-1102, an investigational therapy aimed at…
89bio recently revealed the initiation of the Phase III ENLIGHTEN-Cirrhosis trial of its flagship FGF21 analog, pegozafermin, in patients with…
Private investment firm Blackstone Life Sciences has pulled back the covers on the latest pharma company to hit the immunology…
RAPT Therapeutics has announced plans to terminate two Phase II trials for its lead candidate, zelnecirnon (RPT193), three months after…